Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Executive Vice President | August 12, 2026 | August 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date August 12, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 253,390 |
Reported balance
After 2026-08-12 transaction · row 1
1 source rowRow 1 · 2026-08-12 · Sale · Disposed 146,403 · Balance 253,390 F1: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.40 to $17.67 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.40 to $17.67 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2024 Filed Mar 5, 2024 21:35 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 22,982 | $5.47 | $125,711.54 |
DisclosureSEC source: 0001628280-24-008945 · wk-form4_1709674499.xml · nonDerivative · entry 6 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 391,666 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:35 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 45,871 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-008945 · wk-form4_1709674499.xml · nonDerivative · entry 5 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 414,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock issuable to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:35 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 18,153 | $5.47 | $99,296.91 |
DisclosureSEC source: 0001628280-24-008945 · wk-form4_1709674499.xml · nonDerivative · entry 4 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 368,777 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:35 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 36,232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-008945 · wk-form4_1709674499.xml · nonDerivative · entry 3 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 386,930 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock issuable to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:35 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 28,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-008945 · wk-form4_1709674499.xml · derivative · entry 7 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,958 Underlying: Class A Common Stock · 28,957 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: March 1, 2021, the reporting person was granted 115,830 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: March 1, 2021, the reporting person was granted 115,830 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:35 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 15,181 | $5.47 | $83,040.07 |
DisclosureSEC source: 0001628280-24-008945 · wk-form4_1709674499.xml · nonDerivative · entry 2 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,698 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:35 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 28,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-008945 · wk-form4_1709674499.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock issuable to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:25 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 35,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-007994 · wk-form4_1709241939.xml · derivative · entry 3 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 35,620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On February 27, 2020, the reporting person was granted 142,480 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On February 27, 2020, the reporting person was granted 142,480 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:25 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 18,670 | $5.71 | $106,605.70 |
DisclosureSEC source: 0001628280-24-007994 · wk-form4_1709241939.xml · nonDerivative · entry 2 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,922 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:25 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 35,620 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-007994 · wk-form4_1709241939.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 355,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 23:00 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 366,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016934 · doc4.xml · derivative · entry 5 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,972 Underlying: Class A Common Stock · 366,972 shares Expires not disclosed F6 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F7 · shares: Represents a performance-based restricted stock unit grant of 183,486 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. F7 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 183,486 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. F7 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 183,486 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. F7 · derivative.underlying_shares: Represents a performance-based restricted stock unit grant of 183,486 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. F7 · balance_after: Represents a performance-based restricted stock unit grant of 183,486 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 23:00 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 183,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016934 · doc4.xml · derivative · entry 4 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,486 Underlying: Class A Common Stock · 183,486 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F5 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2024. F5 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2024. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 23:00 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 36,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016934 · doc4.xml · derivative · entry 3 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,696 Underlying: Class A Common Stock · 36,232 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On March 3, 2022, the reporting person was granted 144,928 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On March 3, 2022, the reporting person was granted 144,928 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 23:00 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 18,064 | $1.92 | $34,682.88 |
DisclosureSEC source: 0001209191-23-016934 · doc4.xml · nonDerivative · entry 2 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,972 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 23:00 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 36,232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016934 · doc4.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock issuable to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 28,958 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015519 · doc4.xml · derivative · entry 6 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,915 Underlying: Class A Common Stock · 28,958 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F5 · derivative.exercise_date: On March 1, 2021, the reporting person was granted 115,830 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On March 1, 2021, the reporting person was granted 115,830 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 11,729 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015519 · doc4.xml · derivative · entry 5 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 11,729 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 46,914 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 46,914 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 15,555 | $2.09 | $32,509.95 |
DisclosureSEC source: 0001209191-23-015519 · doc4.xml · nonDerivative · entry 4 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,804 F2 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 28,958 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-015519 · doc4.xml · nonDerivative · entry 3 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock issuable to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 6,504 | $2.09 | $13,593.36 |
DisclosureSEC source: 0001209191-23-015519 · doc4.xml · nonDerivative · entry 2 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,401 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 11,729 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-015519 · doc4.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock issuable to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 35,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014120 · doc4.xml · derivative · entry 3 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,620 Underlying: Class A Common Stock · 35,620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On February 27, 2020, the reporting person was granted 142,480 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On February 27, 2020, the reporting person was granted 142,480 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 19,752 | $2.16 | $42,664.32 |
DisclosureSEC source: 0001209191-23-014120 · doc4.xml · nonDerivative · entry 2 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,176 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 35,620 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014120 · doc4.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 07, 2022 Filed May 10, 2022 22:57 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 4,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028163 · doc4.xml · derivative · entry 3 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 4,442 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| May 07, 2022 Filed May 10, 2022 22:57 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 2,228 | $3.40 | $7,575.20 |
DisclosureSEC source: 0001209191-22-028163 · doc4.xml · nonDerivative · entry 2 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,308 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| May 07, 2022 Filed May 10, 2022 22:57 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 4,442 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-028163 · doc4.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 02:21 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 289,856 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016055 · doc4.xml · derivative · entry 8 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,856 Underlying: Class A Common Stock · 289,856 shares Expires not disclosed F7 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F8 · shares: Represents a performance-based restricted stock unit grant of 144,928 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. F8 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 144,928 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. F8 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 144,928 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. F8 · derivative.underlying_shares: Represents a performance-based restricted stock unit grant of 144,928 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. F8 · balance_after: Represents a performance-based restricted stock unit grant of 144,928 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 02:21 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 144,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016055 · doc4.xml · derivative · entry 7 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,928 Underlying: Class A Common Stock · 144,928 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2023. F6 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2023. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:21 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 28,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016055 · doc4.xml · derivative · entry 6 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,873 Underlying: Class A Common Stock · 28,957 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F5 · derivative.exercise_date: On March 1, 2021, the reporting person was granted 115,830 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On March 1, 2021, the reporting person was granted 115,830 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:21 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 11,728 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016055 · doc4.xml · derivative · entry 5 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,729 Underlying: Class A Common Stock · 11,728 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 46,914 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 46,914 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:21 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 8,905 | $4.45 | $39,627.25 |
DisclosureSEC source: 0001209191-22-016055 · doc4.xml · nonDerivative · entry 4 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,094 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:21 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 28,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-016055 · doc4.xml · nonDerivative · entry 3 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:21 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 3,607 | $4.45 | $16,051.15 |
DisclosureSEC source: 0001209191-22-016055 · doc4.xml · nonDerivative · entry 2 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,042 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:21 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 11,728 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-016055 · doc4.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,649 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| February 27, 2022 Filed Mar 1, 2022 22:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 35,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014142 · doc4.xml · derivative · entry 3 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,240 Underlying: Class A Common Stock · 35,620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On February 27, 2020, the reporting person was granted 142,480 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On February 27, 2020, the reporting person was granted 142,480 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| February 27, 2022 Filed Mar 1, 2022 22:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 11,695 | $4.59 | $53,680.05 |
DisclosureSEC source: 0001209191-22-014142 · doc4.xml · nonDerivative · entry 2 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,921 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| February 27, 2022 Filed Mar 1, 2022 22:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 35,620 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-014142 · doc4.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,616 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 2,000 | $3.95 | $7,900.00 |
DisclosureSEC source: 0001209191-21-070257 · doc4.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,996 Read SEC document |
| May 07, 2021 Filed May 11, 2021 18:55 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 4,441 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-031566 · doc4.xml · derivative · entry 3 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,442 Underlying: Class A Common Stock · 4,441 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| May 07, 2021 Filed May 11, 2021 18:55 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 1,366 | $5.20 | $7,103.20 |
DisclosureSEC source: 0001209191-21-031566 · doc4.xml · nonDerivative · entry 2 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,996 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| May 07, 2021 Filed May 11, 2021 18:55 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 4,441 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-031566 · doc4.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:04 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,330 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001209191-21-021301 · doc4.xml · derivative · entry 3 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,331 Underlying: Class A Common Stock · 36,330 shares Expires 2028-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted on May 7, 2018 and the total award of 72,661 vests in four equal installments on May 7, 2019, May 7, 2020, May 7, 2021 and May 7, 2022. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:04 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 36,330 | $6.87 | $249,489.01 |
DisclosureSEC source: 0001209191-21-021301 · doc4.xml · nonDerivative · entry 2 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,921 F1 · price: This transaction was executed in multiple trades at prices ranging from $6.86 to $6.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:04 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 36,330 | $2.75 | $99,907.50 |
DisclosureSEC source: 0001209191-21-021301 · doc4.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:38 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 11,729 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-016058 · doc4.xml · derivative · entry 6 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,457 Underlying: Class A Common Stock · 11,729 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock units represents a contingent right to receive one share of the Issuer's Class A Common Stock. F5 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 46,914 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 46,914 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:38 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 3,607 | $5.18 | $18,684.26 |
DisclosureSEC source: 0001209191-21-016058 · doc4.xml · nonDerivative · entry 4 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,921 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:38 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 11,729 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-016058 · doc4.xml · nonDerivative · entry 3 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock units represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:05 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 231,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-016996 · doc4.xml · derivative · entry 2 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,660 Underlying: Class A Common Stock · 231,660 shares Expires not disclosed F3 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · shares: Represents the maximum number of shares issuable under the performance-based restricted stock units. F5 · derivative.exercise_date: 50% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. Additional performance-based restricted stock units are earned at higher levels and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10 (75%), $12 (100%), $14 (125%), $16 (150%), $18 (175%) and $20 (200%), respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 29,2024, the last day of the performance period. F5 · derivative.expiration_date: 50% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. Additional performance-based restricted stock units are earned at higher levels and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10 (75%), $12 (100%), $14 (125%), $16 (150%), $18 (175%) and $20 (200%), respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 29,2024, the last day of the performance period. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:05 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 115,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-016996 · doc4.xml · derivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,830 Underlying: Class A Common Stock · 115,830 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2022. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.